365 related articles for article (PubMed ID: 25192738)
1. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial Susceptibility and Molecular Epidemiology of
Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial Non-Susceptibility of Escherichia coli from Outpatients and Patients Visiting Emergency Rooms in Taiwan.
Wang JT; Chang SC; Chang FY; Fung CP; Chuang YC; Chen YS; Shiau YR; Tan MC; Wang HY; Lai JF; Huang IW; Yang Lauderdale TL
PLoS One; 2015; 10(12):e0144103. PubMed ID: 26632819
[TBL] [Abstract][Full Text] [Related]
4. Molecular drivers of emerging multidrug resistance in Proteus mirabilis clinical isolates from Algeria.
Boudjemaa H; Allem R; Fonkou MDM; Zouagui S; Khennouchi NCEH; Kerkoud M
J Glob Antimicrob Resist; 2019 Sep; 18():249-256. PubMed ID: 30797091
[TBL] [Abstract][Full Text] [Related]
5. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
[TBL] [Abstract][Full Text] [Related]
6. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
[TBL] [Abstract][Full Text] [Related]
7. [Plasmid-mediated AMPc producing Proteus mirabilis in the Health Care Area of Santiago de Compostela: molecular and epidemiological analysis by rep-PCR and MALDI-TOF].
Treviño M; Navarro D; Barbeito G; Areses P; García-Riestra C; Regueiro BJ
Rev Esp Quimioter; 2012 Jun; 25(2):122-8. PubMed ID: 22707100
[TBL] [Abstract][Full Text] [Related]
8. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
Mohanty S; Gaind R; Ranjan R; Deb M
J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
[TBL] [Abstract][Full Text] [Related]
9. Molecular epidemiology and antimicrobial susceptibility of AmpC- and/or extended-spectrum (ESBL) ß-lactamaseproducing Proteus spp. clinical isolates in Zenica-Doboj Canton, Bosnia and Herzegovina.
Uzunović S; Ibrahimagić A; Hodžić D; Bedenić B
Med Glas (Zenica); 2016 Aug; 13(2):103-12. PubMed ID: 27313108
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
[TBL] [Abstract][Full Text] [Related]
11. Properties of multidrug-resistant, ESBL-producing Proteus mirabilis isolates and possible role of beta-lactam/beta-lactamase inhibitor combinations.
Luzzaro F; Perilli M; Amicosante G; Lombardi G; Belloni R; Zollo A; Bianchi C; Toniolo A
Int J Antimicrob Agents; 2001 Feb; 17(2):131-5. PubMed ID: 11165117
[TBL] [Abstract][Full Text] [Related]
12. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of a modified double-disc synergy test for detection of extended spectrum beta-lactamases in AMPC beta-lactamase-producing proteus mirabilis.
Khan MK; Thukral SS; Gaind R
Indian J Med Microbiol; 2008; 26(1):58-61. PubMed ID: 18227600
[TBL] [Abstract][Full Text] [Related]
14. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
[TBL] [Abstract][Full Text] [Related]
15. [Resistance to extended-spectrum cephalosporins in non-inducible AmpC enterobacteria: evaluation of the new MIC breakpoints].
Nastro M; Montoto Piazza L; Saposnik E; García S; Barberis C; Vay C; Rodríguez CH; Famiglietti A
Rev Argent Microbiol; 2012; 44(1):30-5. PubMed ID: 22610285
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of Cefotaxime-Resistant Escherichia coli Isolates from Healthy Cattle and Sheep in Northern Spain: Phenotypic and Genome-Based Characterization of Antimicrobial Susceptibility.
Tello M; Ocejo M; Oporto B; Hurtado A
Appl Environ Microbiol; 2020 Jul; 86(15):. PubMed ID: 32471914
[TBL] [Abstract][Full Text] [Related]
17. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
[TBL] [Abstract][Full Text] [Related]
18. Emergence of multidrug-resistant Proteus mirabilis in a long-term care facility in Croatia.
Bedenić B; Firis N; Elveđi-Gašparović V; Krilanović M; Matanović K; Štimac I; Luxner J; Vraneš J; Meštrović T; Zarfel G; Grisold A
Wien Klin Wochenschr; 2016 Jun; 128(11-12):404-13. PubMed ID: 27220339
[TBL] [Abstract][Full Text] [Related]
19. Antimicrobial susceptibility and distribution of extended-spectrum β-lactamases, AmpC β-lactamases and carbapenemases among Proteus, Providencia and Morganella isolated from global hospitalised patients with intra-abdominal and urinary tract infections: Results of the Study for Monitoring Antimicrobial Resistance Trends (SMART), 2008-2011.
Yang JH; Sheng WH; Hsueh PR;
J Glob Antimicrob Resist; 2020 Sep; 22():398-407. PubMed ID: 32311502
[TBL] [Abstract][Full Text] [Related]
20. A simple phenotypic method for differentiation between acquired and chromosomal AmpC beta-lactamases in Escherichia coli.
Mirelis B; Rivera A; Miró E; Mesa RJ; Navarro F; Coll P
Enferm Infecc Microbiol Clin; 2006; 24(6):370-2. PubMed ID: 16792938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
